Cell Stem Cell: Small cell populations play an important role in triggering a silent case of hereditary MDS
"Cell Stem Cell" Small cell populations play an important role in triggering silent cases of hereditary MDS
Lancet Haematol: Venetoclax combined with intensive chemotherapy in the treatment of AML or high-risk MDS
J Clin Oncol: 5-aza+HSCT can significantly improve the survival rate of elderly patients with MDS
Phase II clinical success of eprenetapopt+azacitidine in the treatment of TP53 mutant MDS and AML
Refuge, a shareholding company of 3SBio, cooperates with MD Anderson Cancer Center
The latest clinical application of Eltanexor in the treatment of MDS refractory to demethylation drugs...
The latest clinical data released by Eltanexor in the treatment of MDS refractory to demethylation drugs
Interpretation of the Guidelines for the Treatment of Acute Leukemia and MDS by Allogeneic Transplantation | CSCO Guidelines Conference 2021
Can low-risk MDS benefit from oral azacitidine?
MD Anderson Cancer Center announces long-term follow-up results of R2 regimen in the treatment of follicular lymphoma
Spectral MD, a medical device company, completed a $27 million financing
J Clin Oncol: Eprenetapopt combined with Aza cytosine to treat TP53 mutant MDS and AML
J Clin Oncol: Eprenetapopt combined with Aza cytosine to treat TP53 mutant MDS
Blood: Short telomere length predicts non-recurrence mortality after stem cell transplantation in MDS patients
J Clin Oncol: Intensive conditioning solutions do not improve the prognostic prognostics of allo-HSCT in older patients with high-risk AML/MDS
Deqi ATG-016 treatment MDS has been approved by Phase II clinical trials in China
Clin Cancer Res: Effects of acute and chronic graft resistance to MDS on long-term prognosis after hematogenes transplantation.
Blood: Machine learning reveals the correlation between MDS genotypes and morphological characteristics.
Gilead anti-CD47 monoantigen resistance was identified by the FDA breakthrough therapy to treat MDS.